Overview: Immunosuppressant Drug Profile 4 Panel
Introduction: The Immunosuppressant Drug Profile 4 Panel is a diagnostic tool designed to monitor immunosuppressant levels using whole blood samples. In India, mTOR inhibitors (sirolimus, everolimus) are increasingly used in renal transplantation to reduce calcineurin toxicity and prevent malignancy, requiring therapeutic drug monitoring to maintain efficacy and avoid side effects (hyperlipidemia, delayed wound healing). High morbidity from under-monitoring in rural/low-SES transplant patients, limited TDM labs, delayed dose adjustment leading to rejection or toxicity. Per transplant practices aligned with ICMR and Indian Society of Organ Transplantation guidelines, the test employs immunoassay for sirolimus and everolimus levels over 1-2 days with high accuracy, valuable for routine monitoring in patients on mTOR-based regimens. This diagnostic falls under drug monitoring and targets kidney/heart transplant recipients on sirolimus/everolimus, addressing accurate detection to guide dose titration and toxicity prevention. With elevated morbidity due to under-monitoring, the test supports public health efforts by enabling precise mTOR inhibitor assessment and improving graft/patient survival. Its whole blood-based approach ensures reliable trough level measurement.
Other Names: Immuno Drug 4 Pnl.
FDA Status: FDA approved, CLIA certified for immunology, compliant with 2025 standards.
Historical Milestone: Sirolimus/everolimus TDM standard; in India, expanding in transplant centers.
Purpose: The test assesses 2 parameters including sirolimus level to guide immunosuppressant monitoring, maintain therapeutic range, prevent rejection/toxicity.
Test Parameters: 1. Sirolimus Level, 2. Everolimus Level.
Pretest Condition: No fasting required; patients should be transplant recipients on mTOR inhibitors.
Specimen: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 48 hours with proper handling to preserve drug stability, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not applicable (fresh sample preferred for immunoassay).
Medical History: Patients should provide details on transplant type, current dose, side effects.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of sub/supratherapeutic levels including rejection/toxicity, benefits of monitoring, and minimal discomfort from blood draw.
Procedural Considerations: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret trough levels within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hemolysis, or timing of sample (trough) can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Out-of-range levels indicate need for dose adjustment, necessitating specialist input.
Specialist Consultation: Transplant nephrologists should be consulted for management.
Additional Supporting Tests: Lipid profile, renal function for confirmation.
Test Limitations: Trough only; comprehensive approach required.
References: Indian Journal of Transplantation 2024, Transplant Studies India 2023.
